Quince Therapeutics, Inc. (QNCX): Going concern doubt
Severity scores the disclosed filing signal, not a judgment about the company or its securities.
What was disclosed
ATM program, with approximately $47.5 million remaining available for issuance. Based on our available cash resources and current operating plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the year ended December 31, 2025 are issued.
Why it matters
A going-concern disclosure reflects substantial doubt about the company's ability to continue operating.